High tPA-expression in primary melanoma of the limb correlates with good prognosis
暂无分享,去创建一个
A. Eggermont | U. Kleeberg | H. Straatman | S. Suciu | B. Kroon | F. Lejeune | H. Koops | D. Ruiter | C. Ferrier | G. V. Muijen | W. V. van Geloof | W. V. Geloof | A. Eggermont | G.N.P. van Muijen | G. van Muijen | S. Suciu | H. Straatman | B. B. R. Kroon | F. J. Lejeune | U. R. Kleeberg | Malignant Melanoma Cooperative Group as a side study of tria 18832 | U. Kleeberg | B. Kroon | F. Lejeune
[1] A. Eggermont,et al. Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators , 2000, International journal of cancer.
[2] M. Duffy,et al. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer , 1999, Journal of surgical oncology.
[3] J. Foekens,et al. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer , 1999, British Journal of Cancer.
[4] C. Sweep,et al. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue , 1999, British Journal of Cancer.
[5] H. Engelberg. Actions of heparin that may affect the malignant process , 1999, Cancer.
[6] G. V. van Muijen,et al. Markers of melanocytic tumour progression , 1998, The Journal of pathology.
[7] M. Schmitt,et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). , 1998, International journal of oncology.
[8] M. Carcangiu,et al. Plasminogen activator inhibitor‐1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients , 1998, International journal of cancer.
[9] G. V. van Muijen,et al. Proteases in cutaneous melanoma. , 1998, Annals of medicine.
[10] A. Eggermont,et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] B. Nielsen,et al. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. , 1998, European journal of cancer.
[12] T. Kooistra,et al. Effect of steroid hormones and retinoids on the formation of capillary-like tubular structures of human microvascular endothelial cells in fibrin matrices is related to urokinase expression , 1998 .
[13] J. Biggerstaff,et al. Hemostasis and Malignancy , 1998, Seminars in thrombosis and hemostasis.
[14] D. Ruiter,et al. Epitopes of Components of the Plasminogen Activation System are Re-exposed in Formalin-fixed Paraffin Sections by Different Retrieval Techniques , 1998 .
[15] T. Taguchi,et al. The expression of urokinase type plasminogen activator is a novel prognostic factor in dukes B and C colorectal cancer. , 1998, Oncology reports.
[16] K. Nakanishi,et al. Urokinase‐type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma , 1998 .
[17] W. Anderson,et al. Ability of retroviral transduction to modify the angiogenic characteristics of RPE cells , 1998, Graefe's Archive for Clinical and Experimental Ophthalmology.
[18] M. Carcangiu,et al. Expression of plasminogen activator inhibitor‐2 in epithelial ovarian cancer: A favorable prognostic factor related to the actions of CSF‐1 , 1997, International journal of cancer.
[19] H. Gabbert,et al. Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] T. Hattori,et al. Cellular localization of urokinase‐type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues , 1997, The Journal of pathology.
[21] M. Duffy,et al. The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.
[22] B. Skov,et al. Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry. , 1997, Lung cancer.
[23] T. Taguchi,et al. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. , 1997, Anticancer research.
[24] A. Geurts-Moespot,et al. A Sensitive and Robust Assay for Urokinase and Tissue-Type Plasminogen Activators (Upa and Tpa) and Their Inhibitor Type I (Pai-1) in Breast Tumor Cytosols , 1997, The International journal of biological markers.
[25] T. Huber,et al. Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasmin-independent, receptor-mediated mechanism. , 1996, The Journal of surgical research.
[26] D. Rifkin,et al. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. , 1996, Cancer research.
[27] J. Folkman,et al. Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.
[28] G. V. van Muijen,et al. The plasminogen activation system in melanoma cell lines and in melanocytic lesions. , 1996, Melanoma research.
[29] C. V. D. van de Velde,et al. Prognostic value of the plasminogen activation system in patients with gastric carcinoma , 1996, Cancer.
[30] G. Meadows,et al. Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: Lack of association with In vitro invasion , 1995, International journal of cancer.
[31] A. Nonomura,et al. Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. , 1995, Oncology.
[32] E. Hedley‐Whyte,et al. Prognostic role of urokinase-type plasminogen activator in human gliomas. , 1995, The American journal of pathology.
[33] M. Ogawa,et al. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. , 1995, Surgery.
[34] P. Quax,et al. Components of the plasminogen activation system in uveal melanoma—a clinico‐pathological study , 1995, The Journal of pathology.
[35] H. Kobayashi,et al. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. , 1994, Cancer research.
[36] G. Hu,et al. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Duffy,et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer , 1994, The Lancet.
[38] J. Saurat,et al. Plasminogen activation in melanocytic neoplasia. , 1994, Cancer research.
[39] A. Nakao,et al. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. , 1993, The American journal of gastroenterology.
[40] M. Ogawa,et al. Industrial preparation of poly(vinyl chloride). , 1975, British Journal of Cancer.
[41] K. Kohno,et al. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro. , 1993, Experimental cell research.
[42] M. Kramer,et al. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. , 1992, Experimental cell research.
[43] P. Quax,et al. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation , 1991, The Journal of cell biology.
[44] M. Ploug,et al. Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor , 1991, FEBS letters.
[45] F. Jänicke,et al. Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer , 1991, Seminars in thrombosis and hemostasis.
[46] M. Cardinali,et al. Interaction of fibrinogen with murine melanoma cells: covalent association with cell membranes and protection against recognition by lymphokine-activated killer cells. , 1990, Cancer research.
[47] Y. Gunji,et al. Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. , 1988, Cancer research.
[48] M. Duffy,et al. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. , 1988, Cancer research.
[49] G. Markus. The Role of Hemostasis and Fibrinolysis in the Metastatic Spread of Cancer , 1984, Seminars in thrombosis and hemostasis.
[50] F. Rickles,et al. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. , 1983, Blood.
[51] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[52] R. Fisher,et al. Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. , 1998, Oncology research.
[53] H. Koyama,et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[54] S. Ehrenforth,et al. Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer. , 1997, Cancer detection and prevention.
[55] M. Duffy,et al. Plasminogen activator inhibitor type 2 in breast cancer. , 1997, British Journal of Cancer.
[56] B. M. Mueller. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. , 1996, Current topics in microbiology and immunology.
[57] P. Quax,et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. , 1994, The American journal of pathology.
[58] D. Cox. Regression Models and Life-Tables , 1972 .